Evidence map›Paper›PMID 31727206›Full record

ArticleOncology research2020

Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G₂/M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair.

Nahathai Dukaew, Teruaki Konishi, Kongthawat Chairatvit, Narongchai Autsavapromporn, Noppamas Soonthornchareonnon, Ariyaphong Wongnoppavich

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Journal of biomedical physics & engineering · 2026
    Article
  3. Synergistic Effects of DNA-PKcs Inhibition and Radiotherapy in Esophageal Squamous Cell Carcinoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Article
  5. Article
  6. Quassinoids as Promising Anti-cancer Agents.Current medicinal chemistry · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Nahathai DukaewGraduate/PhD's Degree Program in Biochemistry, Faculty of Medicine, Chiang Mai UniversityChiang MaiThailand.
Teruaki KonishiSingle Cell Radiation Biology Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST)ChibaJapan.
Kongthawat ChairatvitDepartment of Oral Biology, Faculty of Dentistry, Mahidol UniversityBangkokThailand.
Narongchai AutsavaprompornDivision of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chiang Mai UniversityChiang MaiThailand.
Noppamas SoonthornchareonnonDepartment of Pharmacognosy, Faculty of Pharmacy, Mahidol UniversityBangkokThailand.
Ariyaphong WongnoppavichDepartment of Biochemistry, Faculty of Medicine, Chiang Mai UniversityChiang MaiThailand.
Chiang Mai University · THMahidol University · THNational Institutes for Quantum and Radiological Science and Technology · JPPharmac · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) is an important treatment for non-small cell lung cancer (NSCLC). However, the major obstacles to successful RT include the low radiosensitivity of cancer cells and the restricted radiation dose, which is given without damaging normal tissues. Therefore, the sensitizer that increases RT efficacy without dose escalation will be beneficial for NSCLC treatment. Eurycomalactone (ECL), an active quassinoid isolated from

Indexed as

A549 CellsApoptosisCarcinoma, Non-Small-Cell LungCDC2 Protein KinaseCell Cycle CheckpointsCell Line, TumorCell SurvivalCyclin B1DNA Breaks, Double-StrandedDNA RepairEurycomaG2 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansLactonesRadiation-Sensitizing AgentsCDC2 Protein KinaseCyclin B1LactonesRadiation-Sensitizing Agents

Identifiers

PMID31727206
PMCPMC7851521
OpenAlexW2983990244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.